Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ECCO 15 - ESMO 34 /
Round table discussion on targeted therapies for metastatic breast cancer

20th - 24th Sep 2009

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 13.10.09
Views: 8188

Prof McVie discusses the issues with breast cancer experts

How to manage metastatic HER2 positive breast cancer, from the pathology lab, through to hormone therapies, clinical trials and patient involvement in care.

Supported by an unrestricted educational grant from GlaxoSmithKline

Context / Quiz

Targeted therapies for Metastatic Breast Cancer

Expert round table with:

Prof Gordon McVie (Chair)
European Institute of Oncology and ecancermedicalscience, Italy

Prof David Cameron
Director of the National Cancer Research Network, UK

Prof Giuseppe Viale
Director of Pathology and Laboratory Medicine, European Institute of Oncology, Italy

Dr. Deborah Fenlon
Senior Research Fellow, University of Southampton, UK

Prof Hernán Cortés-Funes
Department of Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain.

Target audience

This educational activity is intended for medical, surgical and radiation oncologists, pathologists and nurses as well as allied oncology professionals who treat breast cancer.

Statement of need

Breast cancer is increasing in incidence. Mortality rates in Europe are lower than in the United States, despite greater research output in Europe. Further, within European countries, outcomes between are unacceptably divergent. Much of the problem is translation of research results into clinical practice, which is slower in Europe because of complicated and inefficient communication channels. As a result, adoption of key clinical trials results into guidelines is slow, and uptake of the relevant guidance into everyday clinical practice can take over a year longer than in the USA. The discussion will provide oncologists with an invaluable understanding of metastatic breast cancer and facilitate their practice of evidence-based medicine.

Learning Objective:

After watching the roundtable discussion participants should be able to:

  • Understand the most important factors to consider when treating metastatic breast cancer
  • Understand the pathophysiology of progression and metastasis in breast cancer, and see the logical link to patient management.
  • Know what to take into consideration when deciding on a patient's treatment course
  • Understand the role of targeted therapies in treating ErbB2+/HER2+ women
  • Understand the role of targeted therapies in treating ErbB2+/HER2+/HR +ve women


This scientific information may include data/information on investigational uses of compounds/drugs that have not yet been approved by regulatory authorities.

This material was developed for use outside of the US and is to be used in accordance with local laws and regulations.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation